Urologic approaches to metastatic renal cell carcinoma

Onkologie

Volumn 24, Issue 2, 2001, Pages 122-126

  Mickisch, Gerald H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Metastatic disease; Renal cell carcinoma; Surgery

Indexed keywords

ADJUVANT CHEMOTHERAPY; CANCER SURGERY; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PATIENT SELECTION; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEPHRECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035030968     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050298     Document Type: Review

References (27)

1. Scheltema JMW, Mickisch GH: Mangagement of metastatic renal cell carcinoma: Role of nephrectomy, imunotherapy, failure of chemotherapy and drug resistance. Eur Urol Update Series 1997;6: 27-33.
2. Mickisch GH: No touch nephrectomy: Still a necessity? Eur Urol Update Series 1998;7:115-117.
3. Mickisch GH: Immunotherapy of renal cell carcinoma: A critical appraisal from a urologist's point of view. Urol Int 1999;63:16-21.
4. de Riese W, Goldenberg K, Allhoff E, Stief C, Schlick R, Liedke S, Jonas U: Metastatic renal cell carcinoma (RCC): Spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 1991;23: 3-25.
5. Oliver RTD: Surveillance as a possible option for management of metastatic renal cell carcinoma. Semin Urol 1989;7:149-152.
6. Franklin JR, Figlin R, Belldegrun A: Renal cell carcinoma: Basic biology and clinical behavior. Semin Urol Oncol 1996;14:208-215.
7. Joffe JK, Banks RE, Forbes MA, Hallam S, Jenkins A, Patel PM, Hall GD, Velikova G, Adams J, Crossley A, Johnson PW, Whicher JT, Selby PJ: A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: Clinical data and laboratory evidence of protease activation. Br J Urol 1996;77:638-649.
8. Van Brussel JP, Mickisch GH: Prognostic factors in renal cell and bladder cancer. BJU Int 1999;83: 902-909.
9. Van Poppel H, Baert L: Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belgica 1996;64:11-17.
10. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS: Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261-2266.
11. O'Connell JR, McCaffrey JA, Motzer RJ: What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996;23:17-28.
12. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 1997;158: 1675-1678.
13. Tigrani VS, Reese DM, Small EJ, Presti JC Jr, Carroll PR: Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: A retrospective analysis. Urology 2000;55:36-40.
14. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995;154:32-34
15. Taneja SS, Pierce W, Figlin R, Belldegrun A: Immunotherapy for renal cell carcinoma: the era of interleukin-2 based treatment. Urology 1995;45: 911-914
16. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997;158:1691-1695.
17. Mickisch GH, Garin A, Madej M, de Prijck L, Sylvester R: Value of tumornephrectomy in conjunction with immunotherapy in metastatic renal cell carcinoma: results of a randomized phase III trial (EORTC 30947). Eur Urol 2000;37(suppl 2): 55(abstract 220).
18. Mickisch GH, Garin A, Madej M, de Prijck L, Sylvester R: Tumornephrectomy plus interferon-alpha is superior to interferon-alpha alone in metastatic renal cell carcinoma. J Urol 2000;163(supp): 176(abstract 778).
19. Flanigan RC, Blumenstein BA, Salmon S, Bearman SI, Roy V, Balcerzak SP, McGrath PC, Caton JR, Barlogie B, Crawford ED: Cytoreductive tumornephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949. J Urol 2000;163(suppl):154(abstract 685).
20. Walther MM, Lyne JC, Libutti SK, Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study. Urology 1999;53:496-501.
21. Fleischmann JD, Kim B: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991;145:938-941.
22. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 1999;162:43-45.
23. Rackley R, Novick AC, Klein EA, Bukowski R, McLain D, Goldfarb D: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994;152: 1399-1403.
24. Krishnamurthi V, Novick AC, Bukowski RM: Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 1998;51:933-937.
25. Bukowsky RM: Natural history and therapy of metastatic renal cell carcinoma. Cancer 1997;80: 1198-1220.
26. Lopez Hanninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institutional patients. J Urol 1996; 155:19-25.
27. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-1935.